ARCHIVES

Group Chairmen Reject DCT’s Agenda For Clinical Trials Review, demand Right To Select Speakers

This article is from The Cancer Letter archive.

Vol. 04 No. 26 | June 30, 1978

Download PDF Visit The Full Archive

Related Articles

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

October 28, 2011

Hiring Freeze Squeezes NIH, NCI

August 3, 1979

ASCO Urges Doubling Cooperative Group Program Budget

April 16, 2010

Two Groups Take Different Approaches To Toxicity Of Saltz Regimen In Studies

June 29, 2001

NIH Probing: Double Dipping” Allegation

September 4, 1981

Smokers May Get Cessation Help From Medicare.

January 14, 2005